ArticleJournal of virology2010
Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05680948 (A Roll-Over Observational Study for the Extended Follow-Up of the Volunteers of the ISS T-003 Trial), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Roll-Over Observational Study for the Extended Follow-Up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP2020)
Who cites it
17 citing papers in PubMed.
- HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.Retrovirology · 2015Trial
- Trial
- Editorial: HIV-1 Tat, an enhancer of virus infectivity and disease promoter: target for preventive and therapeutic interventions.Frontiers in immunology · 2026Article
- Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.International journal of molecular sciences · 2024Review
- New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.Archives of virology · 2021Review
- Review
- Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose.Scientific reports · 2019Article
- The role of HIV Tat protein in HIV-related cardiovascular diseases.Journal of translational medicine · 2018Review
- HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.BMC infectious diseases · 2016Article
- Immunogenetic characterization of a captive colony of sooty mangabeys (Cercocebus atys) used for SIV research.Journal of medical primatology · 2015Article
- Article
- Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.PloS one · 2014Article
- Challenges in HIV Vaccine Research for Treatment and Prevention.Frontiers in immunology · 2014Review
- Multilocus definition of MHC haplotypes in pedigreed cynomolgus macaques (Macaca fascicularis).Immunogenetics · 2012Article
- Article
- Variable prevalence and functional diversity of the antiretroviral restriction factor TRIMCyp in Macaca fascicularis.Journal of virology · 2011Article
- Influence of the MHC genotype on the progression of experimental SIV infection in the Mauritian cynomolgus macaque.Immunogenetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The effects of the challenge dose and major histocompatibility complex (MHC) class IB alleles were analyzed in 112 Mauritian cynomolgus monkeys vaccinated (n = 67) or not vaccinated (n = 45) with Tat and challenged with simian/human immunodeficiency virus (SHIV) 89.6P(cy243.) In the controls, the challenge dose (10 to 20 50% monkey infectious doses [MID(50)]) or MHC did not affect susceptibility to infection, peak viral load, or acute CD4 T-cell loss, whereas in the chronic phase of infection, the H1 haplotype correlated with a high viral load (P = 0.0280) and CD4 loss (P = 0.0343). Vaccination reduced the rate of infection acquisition at 10 MID(50) (P < 0.0001), and contained acute CD4 loss at 15 MID(50) (P = 0.0099). Haplotypes H2 and H6 were correlated with increased susceptibility (P = 0.0199) and resistance (P = 0.0087) to infection, respectively. Vaccination also contained CD4 depletion (P = 0.0391) during chronic infection, independently of the challenge dose or haplotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.